These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15189037)

  • 21. DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors.
    Vanommeslaeghe K; Loverix S; Geerlings P; Tourwé D
    Bioorg Med Chem; 2005 Nov; 13(21):6070-82. PubMed ID: 16006131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
    Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
    Grolla AA; Podestà V; Chini MG; Di Micco S; Vallario A; Genazzani AA; Canonico PL; Bifulco G; Tron GC; Sorba G; Pirali T
    J Med Chem; 2009 May; 52(9):2776-85. PubMed ID: 19344175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
    Moradei OM; Mallais TC; Frechette S; Paquin I; Tessier PE; Leit SM; Fournel M; Bonfils C; Trachy-Bourget MC; Liu J; Yan TP; Lu AH; Rahil J; Wang J; Lefebvre S; Li Z; Vaisburg AF; Besterman JM
    J Med Chem; 2007 Nov; 50(23):5543-6. PubMed ID: 17941625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
    Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design.
    Hodawadekar SC; Marmorstein R
    Oncogene; 2007 Aug; 26(37):5528-40. PubMed ID: 17694092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
    Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
    Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
    Bora-Tatar G; Dayangaç-Erden D; Demir AS; Dalkara S; Yelekçi K; Erdem-Yurter H
    Bioorg Med Chem; 2009 Jul; 17(14):5219-28. PubMed ID: 19520580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.
    Wegener D; Hildmann C; Riester D; Schober A; Meyer-Almes FJ; Deubzer HE; Oehme I; Witt O; Lang S; Jaensch M; Makarov V; Lange C; Busse B; Schwienhorst A
    Biochem J; 2008 Jul; 413(1):143-50. PubMed ID: 18384290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches.
    Zhu Y; Li HF; Lu S; Zheng YX; Wu Z; Tang WF; Zhou X; Lu T
    Eur J Med Chem; 2010 May; 45(5):1777-91. PubMed ID: 20153566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies.
    Ragno R; Simeoni S; Rotili D; Caroli A; Botta G; Brosch G; Massa S; Mai A
    Eur J Med Chem; 2008 Mar; 43(3):621-32. PubMed ID: 17698257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of a potent histone deacetylase inhibitor.
    Liu T; Kapustin G; Etzkorn FA
    J Med Chem; 2007 May; 50(9):2003-6. PubMed ID: 17419603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
    Ragno R; Mai A; Massa S; Cerbara I; Valente S; Bottoni P; Scatena R; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2004 Mar; 47(6):1351-9. PubMed ID: 14998325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.